Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Exceptional itemResults restatedNet loss reportedEmphasis of matterResults View source PDF Explain this filing

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.6%Reaction day

₹62.00

prior close

₹58.99

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-3.3% vs market

Pharmaceuticals peers, median of 165sector+0.2%-2.8% vs sector

On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+0.9

15m

+0.9

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.6+0.7-3.3+0.2-2.8

Next day

-7.3+0.7-7.9-0.1-7.1

-7.9+0.0-7.9-0.3-7.6

-5.6-1.1-4.6-1.3-4.3

-6.5+0.0-6.5-1.2-5.3

-6.7+0.3-7.0-1.5-5.2

+1.7+1.1+0.6-0.6+2.2

15d

+12.9+4.9+8.1-0.5+13.4

+17.7+5.3+12.3+2.6+15.0

+3.5+6.9-3.3+4.1-0.6

+20.2+11.9+8.3+7.1+13.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lyka Labs Limited reported audited standalone revenue of Rs 13,469.74 lakhs for FY2026 vs Rs 12,090.53 lakhs in FY2025, showing ~11% revenue growth. However, the company posted a standalone net loss of Rs 3,243.24 lakhs compared to net profit of Rs 810.10 lakhs in the prior year, primarily due to an exceptional impairment charge of Rs 2,301.44 lakhs related to its subsidiary Lyka BDR International Limited. The impairment was triggered by continuous operational losses and severe erosion of the subsidiary's net worth. Consolidated net loss was Rs 1,057.96 lakhs. The company also completed the NCLT-approved merger of Lyka Export Limited (appointed date April 1, 2022), with prior period figures restated from April 1, 2024. Auditors issued an unmodified (clean) opinion though included an Emphasis of Matter paragraph regarding the merger restatement. The company fixed June 4, 2026 as the record date for a scheme-related share issuance.

Likely market impact

The massive impairment charge has driven the company into significant losses for FY2026. Despite modest revenue growth, the write-off of entire exposure to Lyka BDR (Rs 2,301.44 lakhs) severely impacts shareholder value and indicates stress in the subsidiary's business. The share issuance related to the merger adds complexity. Investors should monitor recovery prospects and cash flow generation.